Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab with lenvatinib within its marketing authorisation for treating untreated squamous cell carcinoma of the head and neck.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 5118

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
30 November 2023 For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
31 July 2023 Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations, and further details regarding timings and how you can get involved will be available in due course.
08 June 2023 - 06 July 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 5118
08 June 2023 In progress. Scoping commencing
04 May 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
30 March 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
30 March 2022 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual